Chen Po Yu (Jeff) 4
4 · Alto Neuroscience, Inc. · Filed Feb 7, 2024
Insider Transaction Report
Form 4
Chen Po Yu (Jeff)
Director
Transactions
- Conversion
Common Stock
2024-02-06+39,259→ 39,259 total - Conversion
Series B Preferred Stock
2024-02-06−83,333→ 0 total→ Common Stock (39,259 underlying) - Conversion
Common Stock
2024-02-06+8,450→ 47,709 total - Conversion
Series C Preferred Stock
2024-02-06−18,794→ 0 total→ Common Stock (8,450 underlying)
Footnotes (2)
- [F1]Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date.
- [F2]Each share of Series C Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and had no expiration date.